Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 307285, 8 pages
http://dx.doi.org/10.1155/2015/307285
Research Article

Rat Models of Diet-Induced Obesity and High Fat/Low Dose Streptozotocin Type 2 Diabetes: Effect of Reversal of High Fat Diet Compared to Treatment with Enalapril or Menhaden Oil on Glucose Utilization and Neuropathic Endpoints

1Department of Veterans Affairs Iowa City Health Care System, Iowa City, IA 52246, USA
2Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
3Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA 52242, USA

Received 8 April 2015; Revised 17 June 2015; Accepted 21 June 2015

Academic Editor: Norman Cameron

Copyright © 2015 Amey Holmes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. P. Davidson, L. J. Coppey, A. Holmes, and M. A. Yorek, “Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats,” European Journal of Pharmacology, vol. 677, no. 1–3, pp. 180–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. C. L. Oltman, E. P. Davidson, L. J. Coppey, T. L. Kleinschmidt, B. Dake, and M. A. Yorek, “Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats,” European Journal of Pharmacology, vol. 650, no. 2-3, pp. 556–562, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Coppey, E. Davidson, B. Lu, C. Gerard, and M. Yorek, “Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice,” Neuropharmacology, vol. 60, no. 2-3, pp. 259–266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Yorek, “The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy,” Current Drug Targets, vol. 9, no. 1, pp. 77–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. L. J. Coppey, E. P. Davidson, T. W. Rinehart et al., “ACE inhibition or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats,” Diabetes, vol. 55, no. 2, pp. 341–348, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. M. Manschot, W. H. Gispen, L. J. Kappelle, and G. J. Biessels, “Nerve conduction velocity and evoked potential latencies in streptozotocin-diabetic rats: effects of treatment with an angiotensin converting enzyme inhibitor,” Diabetes/Metabolism Research and Reviews, vol. 19, no. 6, pp. 469–477, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Malik, S. Williamson, C. Abbott et al., “Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial,” The Lancet, vol. 352, no. 9145, pp. 1978–1981, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. E. J. Henriksen and M. Prasannarong, “The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle,” Molecular and Cellular Endocrinology, vol. 378, no. 1-2, pp. 15–22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. D. Premaratna, E. Manickam, D. P. Begg et al., “Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice,” International Journal of Obesity, vol. 36, no. 2, pp. 233–243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. R. S. Weisinger, T. K. Stanley, D. P. Begg, H. S. Weisinger, K. J. Spark, and M. Jois, “Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet,” Physiology and Behavior, vol. 98, no. 1-2, pp. 192–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-Q. Liu, Y. Qiu, Y. Mu et al., “A high ratio of dietary n-3/n-6 polyunsaturated fatty acids improves obesity-linked inflammation and insulin resistance through suppressing activation of TLR4 in SD rats,” Nutrition Research, vol. 33, no. 10, pp. 849–858, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Sarbolouki, M. H. Javanbakht, H. Derakhshanian et al., “Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetic mellitus patients: a double-blind randomized clinical trial,” Singapore Medical Journal, vol. 54, no. 7, pp. 387–390, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Liu, Y. Xue, C. Liu et al., “Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice,” Lipids in Health and Disease, vol. 12, no. 1, article 109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. K. G. Lamping, D. W. Nuno, L. J. Coppey et al., “Modification of high saturated fat diet with n-3 polyunsaturated fat improves glucose intolerance and vascular dysfunction,” Diabetes, Obesity and Metabolism, vol. 15, no. 2, pp. 144–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. L. J. Coppey, E. P. Davidson, A. Obrosov, and M. A. Yorek, “Enriching the diet with menhaden oil improves peripheral neuropathy in streptozotocin-induced type 1 diabetic rats,” Journal of Neurophysiology, vol. 113, no. 3, pp. 701–708, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. T. C. Coste, A. Gerbi, P. Vague, G. Pieroni, and D. Raccah, “Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy,” Diabetes, vol. 52, no. 10, pp. 2578–2585, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Gerbi, J.-M. Maixent, J.-L. Ansaldi et al., “Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats,” Journal of Nutrition, vol. 129, no. 1, pp. 207–213, 1999. View at Google Scholar · View at Scopus
  18. E. P. Davidson, L. J. Coppey, N. A. Calcutt, C. L. Oltman, and M. A. Yorek, “Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 4, pp. 306–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Reed, K. Meszaros, L. J. Entes et al., “A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat,” Metabolism, vol. 49, no. 11, pp. 1390–1394, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P. Ramarao, “Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening,” Pharmacological Research, vol. 52, no. 4, pp. 313–320, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. E. P. Davidson, L. J. Coppey, A. Holmes, B. Dake, and M. A. Yorek, “Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications,” European Journal of Pharmacology, vol. 668, no. 3, pp. 497–506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. S. Al-Goblan, M. A. Al-Alfi, and M. Z. Khan, “Mechanism linking diabetes mellitus and obesity,” Diabetes, Metabolic Syndrome and Obesity, vol. 7, pp. 587–591, 2014. View at Publisher · View at Google Scholar
  23. N. Esser, S. Legrand-Poels, J. Piette, A. J. Scheen, and N. Paquot, “Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 105, no. 2, pp. 141–150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. U. J. Jung and M.-S. Choi, “Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease,” International Journal of Molecular Sciences, vol. 15, no. 4, pp. 6184–6223, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Matsuda and I. Shimomura, “Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer,” Obesity Research and Clinical Practice, vol. 7, no. 5, pp. e330–e341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Cortez, J. R. Singleton, and A. G. Smith, “Glucose intolerance, metabolic syndrome, and neuropathy,” in Handbook Clinical Neurology, vol. 126, pp. 109–122, 2014. View at Google Scholar
  27. S. Divisova, E. Vlckova, M. Hnojcikova et al., “Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres,” Journal of the Peripheral Nervous System, vol. 17, no. 3, pp. 341–350, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Papanas and D. Ziegler, “Prediabetic neuropathy: does it exist?” Current Diabetes Reports, vol. 12, no. 4, pp. 376–383, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Papanas, A. I. Vinik, and D. Ziegler, “Neuropathy in prediabetes: does the clock start ticking early?” Nature Reviews Endocrinology, vol. 7, no. 11, pp. 682–690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. L. J. Coppey, A. Holmes, E. P. Davidson, and M. A. Yorek, “Partial replacement with menhaden oil improves peripheral neuropathy in high-fat-fed low-dose streptozotocin type 2 diabetic rat,” Journal of Nutrition and Metabolism, vol. 2012, Article ID 950517, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. K. K. Beiswenger, N. A. Calcutt, and A. P. Mizisin, “Epidermal nerve fiber quantification in the assessment of diabetic neuropathy,” Acta Histochemica, vol. 110, no. 5, pp. 351–362, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. E. P. Davidson, L. J. Coppey, B. Dake, and M. A. Yorek, “Effect of treatment of sprague dawley rats with AVE7688, enalapril, or candoxatril on diet-induced obesity,” Journal of Obesity, vol. 2011, Article ID 686952, 9 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. L. D. M. Zeve, C. A. B. Tomaz, P. A. N. Nassif, J. H. Lima, L. R. Z. Sansana, and C. H. Zeve, “Obese patients with diabetes mellitus type 2 undergoing gastric bypass in Roux-en-Y: analysis of results and its influence in complications,” Arquivos Brasileiros de Cirurgia Digestiva, vol. 26, pp. 47–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. A. B. Crugeiras, M. C. Carreira, B. Cabia, S. Andrade, M. Amil, and F. F. Casanueva, “Leptin resistance in obesity: an epigenetic landscape,” Life Sciences, 2015. View at Publisher · View at Google Scholar
  35. N. F. Sheard, “Moderate changes in weight and physical activity can prevent or delay the development of type 2 diabetes mellitus in susceptible individuals,” Nutrition Reviews, vol. 61, no. 2, pp. 76–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. J. P. Foreyt and W. S. Poston, “The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient,” International Journal of Obesity, vol. 7, pp. S5–S11, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. J. R. Singleton, R. L. Marcus, J. E. Jackson, M. K. Lessard, T. E. Graham, and A. G. Smith, “Exercise increases cutaneous nerve density in diabetic patients without neuropathy,” Annals of Clinical and Translational Neurology, vol. 1, no. 10, pp. 844–849, 2014. View at Publisher · View at Google Scholar
  38. J. R. Singleton, R. L. Marcus, M. K. Lessard, J. E. Jackson, and A. G. Smith, “Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients,” Annals of Neurology, vol. 77, no. 1, pp. 146–153, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Dixit, A. G. Maiya, and B. A. Shastry, “Effect of aerobic exercise on peripheral nerve functions of population with diabetic peripheral neuropathy in type 2 diabetes: a single blind, parallel group randomized controlled trial,” Journal of Diabetes and its Complications, vol. 28, no. 3, pp. 332–339, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Y. Jin, K. A. Lee, and T. S. Park, “The effect of exercise on the peripheral nerve in streptozotocin (STZ)-induced diabetic rats,” Endocrine, vol. 48, no. 3, pp. 826–833, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. C. L. Oltman, E. P. Davidson, L. J. Coppey et al., “Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse,” Diabetes, Obesity and Metabolism, vol. 10, no. 1, pp. 64–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Shevalye, M. S. Yorek, L. J. Coppey et al., “Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes,” Journal of Neurophysiology, 2015. View at Publisher · View at Google Scholar